GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (NAS:ITCI) » Definitions » Cash Conversion Cycle

Intra-Cellular Therapies (Intra-Cellular Therapies) Cash Conversion Cycle : 214.02 (As of Dec. 2023)


View and export this data going back to 2013. Start your Free Trial

What is Intra-Cellular Therapies Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Intra-Cellular Therapies's Days Sales Outstanding for the three months ended in Dec. 2023 was 75.18.
Intra-Cellular Therapies's Days Inventory for the three months ended in Dec. 2023 was 232.91.
Intra-Cellular Therapies's Days Payable for the three months ended in Dec. 2023 was 94.07.
Therefore, Intra-Cellular Therapies's Cash Conversion Cycle (CCC) for the three months ended in Dec. 2023 was 214.02.


Intra-Cellular Therapies Cash Conversion Cycle Historical Data

The historical data trend for Intra-Cellular Therapies's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Cash Conversion Cycle Chart

Intra-Cellular Therapies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Conversion Cycle
Get a 7-Day Free Trial Premium Member Only Premium Member Only - 288.51 87.48 183.94 148.91

Intra-Cellular Therapies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 225.29 301.38 417.89 404.56 214.02

Competitive Comparison of Intra-Cellular Therapies's Cash Conversion Cycle

For the Drug Manufacturers - Specialty & Generic subindustry, Intra-Cellular Therapies's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Intra-Cellular Therapies's Cash Conversion Cycle Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Intra-Cellular Therapies's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Intra-Cellular Therapies's Cash Conversion Cycle falls into.



Intra-Cellular Therapies Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Intra-Cellular Therapies's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=74.71+192.35-118.15
=148.91

Intra-Cellular Therapies's Cash Conversion Cycle for the quarter that ended in Dec. 2023 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=75.18+232.91-94.07
=214.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Intra-Cellular Therapies  (NAS:ITCI) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Intra-Cellular Therapies Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Intra-Cellular Therapies (Intra-Cellular Therapies) Business Description

Traded in Other Exchanges
Address
430 East 29th Street, New York, NY, USA, 10016
Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.
Executives
Sharon Mates director, officer: Chairman, President & CEO C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Michael Halstead officer: SVP and General Counsel C/O WARNER CHILCOTT CORPORATION, 100 ENTERPRISE DRIVE, ROCKAWAY NJ 07866
Suresh K. Durgam officer: Chief Medical Officer C/O INTER-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Mark Neumann officer: EVP, Chief Commercial Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Lawrence J. Hineline officer: VP of Finance, CFO & Secretary C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Van Nostrand Robert L director C/O ACHILLION PHARMACEUTICALS, INC., 300 GEORGE STREET, NEW HAVEN CT 06511
Joel S Marcus director C/O ALEXANDRIA REAL ESTATE EQUITIES, INC, 26 NORTH EUCLID AVENUE, PASADENA CA 91101
Eduardo Rene Salas director C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Rory B Riggs director 65 RAILROAD AVE, RIDGEFIELD NJ 07657
Christopher D Alafi director, 10 percent owner P.O. BOX 7338, BERKELEY CA 94707
Richard A Lerner director THE SCRIPPS RESEARCH INSTITUTE, 10550 N. TORREY PINES ROAD, LA JOLLA CA 92037
Andrew Satlin officer: EVP and Chief Medical Officer C/O INTRA-CELLULAR THERAPIES, INC., 430 EAST 29TH STREET, NEW YORK NY 10016
Kimberly E. Vanover officer: VP, Clinical Development C/O INTRA-CELLULAR THERAPIES, INC., 3960 BROADWAY, NEW YORK NY 10032
Robert E Davis officer: SVP, Chief Scientific Officer 3911 SORRENTO VALLEY BOULEVARD, SAN DIEGO CA 92121
Moshe Alafi 10 percent owner 1311 ORLEANS DRIVE, SUNNYVALE CA 94089

Intra-Cellular Therapies (Intra-Cellular Therapies) Headlines